{"title": "COVID-19-Impfstoffe", "author": null, "url": "https://www.pei.de/DE/arzneimittel/impfstoffe/covid-19/covid-19-node.html", "hostname": "pei.de", "description": "COVID-19-Impfstoffe", "sitename": "pei.de", "date": "2023-09-15", "id": null, "license": null, "body": null, "comments": "", "commentsbody": null, "raw_text": null, "text": "|\n|\nBimervax\n|\n|\nCOVID-19-Impfstoff (Proteinbasierter Impfstoff, rekombinant, adjuvantiert)\nVerwendung als Auffrischimpfung ab einem Lebensalter von 16 Jahren / Use as Booster dose from 16 years of age onwards\n|\n|\nHIPRA Human Health, S.L.U., Spanien\n|Bivalent\n||EU/1/22/1709\n||30.03.2023\n||\n|\n[EPAR: Bimervax](https://www.ema.europa.eu/en/medicines/human/EPAR/bimervax)\n[Product Information: Bimervax](https://www.ema.europa.eu/documents/product-information/bimervax-epar-product-information_en.pdf)\n|\n|\nComirnaty\n|\n|\nCOVID-19-Impfstoff (mRNA)\nVerwendung ab einem Lebensalter von 12 Jahren / Use from 12 years of age onwards\n|\n|\nBioNTech Manufacturing GmbH\n|Mono\n||EU/1/20/1528\n||21.12.2020\n||\n|\n[EPAR: Comirnaty](https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty)\n[Produktinformation: Comirnaty](https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_de.pdf)\n[Product Information: Comirnaty](https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_en.pdf)\n[Rote-Hand-Brief: BioNTech und Moderna zu den Impfstoffen Comirnaty und Spikevax (19.07.2021)](/SharedDocs/Downloads/DE/newsroom/veroeffentlichungen-arzneimittel/rhb/21-07-19-covid-19-comirnaty-und-spikevax.pdf?__blob=publicationFile&v=5)\n|\n|\nComirnaty (3 \u00b5g)\n|\n|\nCOVID-19-Impfstoff (mRNA)\nVerwendung in einem Lebensalter von 6 Monaten bis 4 Jahren / Use from 6 months to 4 years of age\n|\n|\nBioNTech Manufacturing GmbH\n|Mono\n||EU/1/20/1528\n||21.12.2020\n||\n|\nZulassungserweiterung /\nMarketing Authorisation Extension\n20.10.2022\n[EPAR: Comirnaty](https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty)\n[Produktinformation: Comirnaty](https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_de.pdf)\n[Product Information: Comirnaty](https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_en.pdf)\n|\n|\nComirnaty (10 \u00b5g)\n|\n|\nCOVID-19-Impfstoff (mRNA)\nVerwendung in einem Lebensalter von 5 bis 11 Jahren / Use from 5 to 11 years of age\n|\n|\nBioNTech Manufacturing GmbH\n|Mono\n||EU/1/20/1528\n||21.12.2020\n||\n|\nZulassungserweiterung /\nMarketing Authorisation Extension\n26.11.2021\n[EPAR: Comirnaty](https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty)\n[Produktinformation: Comirnaty](https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_de.pdf)\n[Product Information: Comirnaty](https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_en.pdf)\n|\n|\nComirnaty Omicron XBB.1.5 (3 \u00b5g)\n|\n|\nCOVID-19-Impfstoff (mRNA)\nVerwendung ab einem Lebensalter von 6 Monaten bis 4 Jahren / Use from 6 months to 4 years of age\n|\n|\nBioNTech Manufacturing GmbH\n|Mono\n||EU/1/20/1528\n||21.12.2020\n||\n|\nZulassungserweiterung /\nMarketing Authorisation Extension\n31.08.2023\n[EPAR: Comirnaty](https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty)\n[Produktinformation: Comirnaty](https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_de.pdf)\n[Product Information: Comirnaty](https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_en.pdf)\n|\n|\nComirnaty Omicron XBB.1.5 (10 \u00b5g)\n|\n|\nCOVID-19-Impfstoff (mRNA)\nVerwendung in einem Lebensalter von 5 bis 11 Jahren / Use from 5 to 11 years of age\n|\n|\nBioNTech Manufacturing GmbH\n|Mono\n||EU/1/20/1528\n||21.12.2020\n||\n|\nZulassungserweiterung /\nMarketing Authorisation Extension\n31.08.2023\n[EPAR: Comirnaty](https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty)\n[Produktinformation: Comirnaty](https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_de.pdf)\n[Product Information: Comirnaty](https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_en.pdf)\n|\n|\nComirnaty Omicron XBB.1.5 (30 \u00b5g)\n|\n|\nCOVID-19-Impfstoff (mRNA)\nVerwendung ab einem Lebensalter von 12 Jahren / Use from 12 years of age onwards\n|\n|\nBioNTech Manufacturing GmbH\n|Mono\n||EU/1/20/1528\n||21.12.2020\n||\n|\nZulassungserweiterung /\nMarketing Authorisation Extension\n31.08.2023\n[EPAR: Comirnaty](https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty)\n[Produktinformation: Comirnaty](https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_de.pdf)\n[Product Information: Comirnaty](https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_en.pdf)\n|\n|\nComirnaty Original/Omicron BA.1\n|\n|\nCOVID-19-Impfstoff (mRNA)\nVerwendung als Auffrischimpfung ab einem Lebensalter von 12 Jahren / Use as Booster dose from 12 years of age onwards\n|\n|\nBioNTech Manufacturing GmbH\n|Bivalent\n||EU/1/20/1528\n||21.12.2020\n||\n|\nZulassungserweiterung /\nMarketing Authorisation Extension\n01.09.2022\n[EPAR: Comirnaty](https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty)\n[Produktinformation: Comirnaty](https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_de.pdf)\n[Product Information: Comirnaty](https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_en.pdf)\n|\n|\nComirnaty Original/Omicron BA.4-5\n|\n|\nCOVID-19-Impfstoff (mRNA)\nVerwendung ab einem Lebensalter von 12 Jahren / Use from 12 years of age onwards\n|\n|\nBioNTech Manufacturing GmbH\n|Bivalent\n||EU/1/20/1528\n||21.12.2020\n||\n|\nZulassungserweiterungen /\nMarketing Authorisation Extensions\n12.09.2022\n08.08.2023\n[EPAR: Comirnaty](https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty)\n[Produktinformation: Comirnaty](https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_de.pdf)\n[Product Information: Comirnaty](https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_en.pdf)\n|\n|\nComirnaty Original/Omicron BA.4-5 (1,5/1,5 \u00b5g)\n|\n|\nCOVID-19-Impfstoff (mRNA)\nVerwendung in einem Lebensalter von 6 Monaten bis 4 Jahren / Use from 6 months to 4 years of age\n|\n|\nBioNTech Manufacturing GmbH\n|Bivalent\n||EU/1/20/1528\n||21.12.2020\n||\n|\nZulassungserweiterung /\nMarketing Authorisation Extension\n08.08.2023\n[EPAR: Comirnaty](https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty)\n[Produktinformation: Comirnaty](https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_de.pdf)\n[Product Information: Comirnaty](https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_en.pdf)\n|\n|\nComirnaty Original/Omicron BA.4-5 (5/5 \u00b5g)\n|\n|\nCOVID-19-Impfstoff (mRNA)\nVerwendung in einem Lebensalter von 5 bis 11 Jahren / Use from 5 to 11 years of age\n|\n|\nBioNTech Manufacturing GmbH\n|Bivalent\n||EU/1/20/1528\n||21.12.2020\n||\n|\nZulassungserweiterungen /\nMarketing Authorisation Extensions\n10.11.2022\n08.08.2023\n[EPAR: Comirnaty](https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty)\n[Produktinformation: Comirnaty](https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_de.pdf)\n[Product Information: Comirnaty](https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_en.pdf)\n|\n|\nCOVID-19 Vaccine (inactivated, adjuvanted) Valneva\n|\n|\nCOVID-19-Impfstoff (Virusimpfstoff, inaktiviert, adjuvantiert)\nVerwendung in einem Lebensalter von 18 bis 50 Jahren / Use from 18 to 50 years of age\n|\n|\nValneva Austria GmbH\n|Mono\n||EU/1/21/1624\n||24.06.2022\n||\n|\n[EPAR: COVID-19 Vaccine (inactivated, adjuvanted) Valneva](https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-inactivated-adjuvanted-valneva)\n[Produktinformation: COVID-19 Vaccine (inactivated, adjuvanted) Valneva](https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-product-information_de.pdf)\n[Product Information: COVID-19 Vaccine (inactivated, adjuvanted) Valneva](https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-product-information_en.pdf)\n|\n|\nCOVID-19 Vaccine (inactivated, adjuvanted) Valneva\n|\n|\nCOVID-19-Impfstoff (Virusimpfstoff, inaktiviert, adjuvantiert)\nVerwendung als Auffrischimpfung in einem Lebensalter von 18 bis 50 Jahren / Use as booster dose from 18 to 50 years of age\n|\n|\nValneva Austria GmbH\n|Mono\n||EU/1/21/1624\n||24.06.2022\n||\n|\nZulassungserweiterung /\nMarketing Authorisation Extension\n24.03.2023\n[EPAR: COVID-19 Vaccine (inactivated, adjuvanted) Valneva](https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-inactivated-adjuvanted-valneva)\n[Produktinformation: COVID-19 Vaccine (inactivated, adjuvanted) Valneva](https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-product-information_de.pdf)\n[Product Information: COVID-19 Vaccine (inactivated, adjuvanted) Valneva](https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-product-information_en.pdf)\n|\n|\nJcovden (COVID-19 Vaccine Janssen)\n|\n|\nCOVID-19-Impfstoff (Vektor-Impfstoff)\nVerwendung ab einem Lebensalter von 18 Jahren / Use from 18 years of age onwards\n|\n|\nJanssen-Cilag International NV\n|Mono\n||EU/1/20/1525\n||11.03.2021\n||\n|\n[EPAR: Jcovden (COVID-19 Vaccine Janssen)](https://www.ema.europa.eu/en/medicines/human/EPAR/jcovden-previously-covid-19-vaccine-janssen)\n[Produktinformation: Jcovden (COVID-19 Vaccine Janssen)](https://www.ema.europa.eu/documents/product-information/jcovden-previously-covid-19-vaccine-janssen-epar-product-information_de.pdf)\n[Product Information: Jcovden (COVID-19 Vaccine Janssen)](https://www.ema.europa.eu/documents/product-information/jcovden-previously-covid-19-vaccine-janssen-epar-product-information_en.pdf)\n[Rote-Hand-Brief: COVID-19 Vaccine Janssen (13.10.2021)](/SharedDocs/Downloads/DE/newsroom/veroeffentlichungen-arzneimittel/rhb/21-10-13-covid-19-vaccine-janssen.pdf?__blob=publicationFile&v=2)\n[Rote-Hand-Brief: COVID-19 Vaccine Janssen (19.07.2021)](/SharedDocs/Downloads/DE/newsroom/veroeffentlichungen-arzneimittel/rhb/21-07-19-covid-19-vaccine-janssen.pdf?__blob=publicationFile&v=4)\n[Rote-Hand-Brief: COVID-19 Vaccine Janssen (26.04.2021)](/SharedDocs/Downloads/DE/newsroom/veroeffentlichungen-arzneimittel/rhb/21-04-26-covid-19-vaccine-janssen.pdf?__blob=publicationFile&v=3)\n|\n|\nNuvaxovid (NVX-CoV2373)\n|\n|\nCOVID-19-Impfstoff (Proteinbasierter Impfstoff)\nVerwendung ab einem Lebensalter von 12 Jahren / Use from 12 years of age onwards\n|\n|\nNovavax CZ a.s.\n|Mono\n||EU/1/21/1618\n||20.12.2021\n||\n|\n[EPAR: Nuvaxovid](https://www.ema.europa.eu/en/medicines/human/EPAR/nuvaxovid)\n[Produktinformation: Nuvaxovid](https://www.ema.europa.eu/en/documents/product-information/nuvaxovid-epar-product-information_de.pdf)\n[Product Information: Nuvaxovid](https://www.ema.europa.eu/en/documents/product-information/nuvaxovid-epar-product-information_en.pdf)\n|\n|\nSpikevax (COVID-19 Vaccine Moderna)\n|\n|\nCOVID-19-Impfstoff (mRNA)\nVerwendung ab einem Lebensalter von 12 Jahren / Use from 12 years of age onwards\n|\n|\nModerna Biotech Spain, S.L.\n|Mono\n||EU/1/20/1507\n||06.01.2021\n||\n|\n[EPAR: Spikevax (COVID-19 Vaccine Moderna)](https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-moderna)\n[Produktinformation: Spikevax (COVID-19 Vaccine Moderna)](https://www.ema.europa.eu/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_de.pdf)\n[Product Information: Spikevax (COVID-19 Vaccine Moderna)](https://www.ema.europa.eu/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_en.pdf)\n[Rote-Hand-Brief: BioNTech und Moderna zu den Impfstoffen Comirnaty und Spikevax (19.07.2021)](/SharedDocs/Downloads/DE/newsroom/veroeffentlichungen-arzneimittel/rhb/21-07-19-covid-19-comirnaty-und-spikevax.pdf?__blob=publicationFile&v=5)\n|\n|\nSpikevax (COVID-19 Vaccine Moderna) (25 \u00b5g)\n|\n|\nCOVID-19-Impfstoff (mRNA)\nVerwendung ab einem Lebensalter von 6 Monaten bis 5 Jahren / Use from 6 months to 5 years of age\n|\n|\nModerna Biotech Spain, S.L.\n|Mono\n||EU/1/20/1507\n||06.01.2021\n||\n|\nZulassungserweiterung /\nMarketing Authorisation Extension\n20.10.2022\n[EPAR: Spikevax (COVID-19 Vaccine Moderna)](https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-moderna)\n[Produktinformation: Spikevax (COVID-19 Vaccine Moderna)](https://www.ema.europa.eu/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_de.pdf)\n[Product Information: Spikevax (COVID-19 Vaccine Moderna)](https://www.ema.europa.eu/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_en.pdf)\n|\n|\nSpikevax (COVID-19 Vaccine Moderna) (50 \u00b5g)\n|\n|\nCOVID-19-Impfstoff (mRNA)\nVerwendung ab einem Lebensalter von 6 bis 11 Jahren / Use from 6 to 11 years of age\n|\n|\nModerna Biotech Spain, S.L.\n|Mono\n||EU/1/20/1507\n||06.01.2021\n||\n|\nZulassungserweiterung /\nMarketing Authorisation Extension\n02.03.2022\n[EPAR: Spikevax (COVID-19 Vaccine Moderna)](https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-moderna)\n[Produktinformation: Spikevax (COVID-19 Vaccine Moderna)](https://www.ema.europa.eu/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_de.pdf)\n[Product Information: Spikevax (COVID-19 Vaccine Moderna)](https://www.ema.europa.eu/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_en.pdf)\n|\n|\nSpikevax (COVID-19 Vaccine Moderna) (50 \u00b5g)\n|\n|\nCOVID-19-Impfstoff (mRNA)\nVerwendung als Auffrischimpfung ab einem Lebensalter von 6 Jahren / Use as Booster dose from 6 years of age onwards\n|\n|\nModerna Biotech Spain, S.L.\n|Mono\n||EU/1/20/1507\n||06.01.2021\n||\n|\nZulassungserweiterungen /\nMarketing Authorisation Extensions\n25.10.2021\n16.12.2022\n[EPAR: Spikevax (COVID-19 Vaccine Moderna)](https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-moderna)\n[Produktinformation: Spikevax (COVID-19 Vaccine Moderna)](https://www.ema.europa.eu/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_de.pdf)\n[Product Information: Spikevax (COVID-19 Vaccine Moderna)](https://www.ema.europa.eu/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_en.pdf)\n|\n|\nSpikevax bivalent Original/Omicron BA.1\n|\n|\nCOVID-19-Impfstoff (mRNA)\nVerwendung als Auffrischimpfung ab einem Lebensalter von 6 Jahren / Use as Booster dose from 6 years of age onwards\n|\n|\nModerna Biotech Spain, S.L.\n|Bivalent\n||EU/1/20/1507\n||06.01.2021\n||\n|\nZulassungserweiterungen /\nMarketing Authorisation Extensions\n01.09.2022\n16.12.2022\n[EPAR: Spikevax (COVID-19 Vaccine Moderna)](https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-moderna)\n[Produktinformation: Spikevax (COVID-19 Vaccine Moderna)](https://www.ema.europa.eu/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_de.pdf)\n[Product Information: Spikevax (COVID-19 Vaccine Moderna)](https://www.ema.europa.eu/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_en.pdf)\n|\n|\nSpikevax bivalent Original/Omicron BA.4-5\n|\n|\nCOVID-19-Impfstoff (mRNA)\nVerwendung ab einem Lebensalter von 6 Monaten / Use from 6 months of age onwards\n|\n|\nModerna Biotech Spain, S.L.\n|Bivalent\n||EU/1/20/1507\n||06.01.2021\n||\n|\nZulassungserweiterungen /\nMarketing Authorisation Extensions\n20.10.2022\n26.05.2023\n11.08.2023\n[EPAR: Spikevax (COVID-19 Vaccine Moderna)](https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-moderna)\n[Produktinformation: Spikevax (COVID-19 Vaccine Moderna)](https://www.ema.europa.eu/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_de.pdf)\n[Product Information: Spikevax (COVID-19 Vaccine Moderna)](https://www.ema.europa.eu/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_en.pdf)\n|\n|\nSpikevax XBB.1.5\n|\n|\nCOVID-19-Impfstoff (mRNA)\nVerwendung ab einem Lebensalter von 6 Monaten / Use from 6 months of age onwards\n|\n|\nModerna Biotech Spain, S.L.\n|Mono\n||EU/1/20/1507\n||06.01.2021\n||\n|\nZulassungserweiterung /\nMarketing Authorisation Extension\n15.09.2023\n[EPAR: Spikevax (COVID-19 Vaccine Moderna)](https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-moderna)\n[Produktinformation: Spikevax (COVID-19 Vaccine Moderna)](https://www.ema.europa.eu/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_de.pdf)\n[Product Information: Spikevax (COVID-19 Vaccine Moderna)](https://www.ema.europa.eu/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_en.pdf)\n|\n|\nVaxzevria (COVID-19 Vaccine AstraZeneca)\n|\n|\nCOVID-19-Impfstoff (Vektor-Impfstoff)\nVerwendung ab einem Lebensalter von 18 Jahren / Use from 18 years of age onwards\n|\n|\nAstraZeneca AB, Schweden\n|Mono\n||EU/1/21/1529\n||29.01.2021\n||\n|\n[EPAR: Vaxzevria (COVID-19 Vaccine AstraZeneca)](https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-astrazeneca)\n[Product Information: Vaxzevria (COVID-19 Vaccine AstraZeneca)](https://www.ema.europa.eu/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_en.pdf)\n[Rote-Hand-Brief: Vaxzevria / COVID-19 Vaccine AstraZeneca (13.10.2021)](/SharedDocs/Downloads/DE/newsroom/veroeffentlichungen-arzneimittel/rhb/21-10-13-covid-19-vaccine-vaxzevria.pdf?__blob=publicationFile&v=2)\n[Rote-Hand-Brief: Vaxzevria / COVID-19 Vaccine AstraZeneca (23.06.2021)](/SharedDocs/Downloads/DE/newsroom/veroeffentlichungen-arzneimittel/rhb/21-06-23-covid-19-vaccine-vaxzevria.pdf?__blob=publicationFile&v=2)\n[Rote-Hand-Brief: Vaxzevria / COVID-19 Vaccine AstraZeneca (02.06.2021)](/SharedDocs/Downloads/DE/newsroom/veroeffentlichungen-arzneimittel/rhb/21-06-02-covid-19-vaccine-vaxzevria.pdf?__blob=publicationFile&v=3)\n[Rote-Hand-Brief: Vaxzevria / COVID-19 Vaccine AstraZeneca (13.04.2021)](/SharedDocs/Downloads/DE/newsroom/veroeffentlichungen-arzneimittel/rhb/21-04-13-covid-19-vaccine-astrazeneca.pdf?__blob=publicationFile&v=4)\n[Rote-Hand-Brief: COVID-19 Vaccine AstraZeneca (24.03.2021)](/SharedDocs/Downloads/DE/newsroom/veroeffentlichungen-arzneimittel/rhb/21-03-23-covid-19-vaccine-astrazeneca.pdf?__blob=publicationFile&v=2)\n[19.03.2021: Information f\u00fcr \u00c4rztinnen und \u00c4rzte - COVID-19-Impfstoff AstraZeneca](/SharedDocs/Downloads/DE/newsroom/mitteilungen/210319-aerzte-sicherheit-astrazeneca.pdf?__blob=publicationFile&v=6)\n[19.03.2021: Information for Physicians - COVID-19 Vaccine AstraZeneca](SharedDocs/Downloads/EN/newsroom-en/notification/210319-information-physicians-astrazeneca.html?nn=221090)\n|\n|\nVidPrevtyn Beta\n|\n|\nCOVID-19-Impfstoff (Proteinbasierter Impfstoff, rekombinant, adjuvantiert)\nVerwendung als Auffrischimpfung ab einem Lebensalter von 18 Jahren / Use as Booster dose from 18 years of age onwards\n|\n|\nSanofi Pasteur, Frankreich\n|Mono\n||EU/1/21/1580\n||10.11.2022\n||\n|\n[EPAR: VidPrevtyn Beta](https://www.ema.europa.eu/en/medicines/human/EPAR/vidprevtyn-beta)\n[Produktinformation: VidPrevtyn Beta](https://www.ema.europa.eu/en/documents/product-information/vidprevtyn-beta-epar-product-information_de.pdf)\n[Product Information: VidPrevtyn Beta](https://www.ema.europa.eu/en/documents/product-information/vidvidprevtyn-beta-epar-product-information_en.pdf)", "language": null, "image": null, "pagetype": null, "links": [null, "DE/arzneimittel/impfstoffe/covid-19/covid-19-node.html#content", "DE/arzneimittel/impfstoffe/covid-19/covid-19-node.html#navPrimary", "DE/service-navi/suche/suche_node.html", "DE/service-navi/datenschutz/datenschutz-node.html", "#", "DE/service/faq/faq-node.html", "DE/newsroom/social-media/social-media-node.html", "DE/footer-kopfleiste/rss/rss-node.html", "DE/service/karriere/karriere-node.html", "DE/service/presse/presse-node.html", "DE/service-navi/kontakt/kontakt_node.html", "EN/medicinal-products/vaccines-human/covid-19/covid-19-list-1.html", "DE/home/home-node.html", null, "DE/institut/institut-node.html", "DE/institut/aufgaben/aufgaben-node.html", "DE/institut/leitprinzipien/leitprinzipien-node.html", "DE/institut/organisation/organisation-node.html", "DE/institut/zepai/zentrum-pandemie-impfstoffe-therapeutika-node.html", "DE/institut/pei-international/pei-international-node.html", "DE/institut/who-kooperationszentren/who-kooperationszentren-node.html", "DE/institut/neubau/neubau-node.html", "DE/institut/geschichte-paul-ehrlich-institut/geschichte-paul-ehrlich-institut-node.html", "DE/institut/paul-ehrlich/paul-ehrlich-im-portrait-node.html", "DE/institut/biologischer-verein/biologischer-verein-node.html", "DE/arzneimittel/arzneimittel-node.html", "DE/arzneimittel/impfstoffe/impfstoffe-node.html", "DE/arzneimittel/allergene/allergene-node.html", "DE/arzneimittel/antikoerper/antikoerper-node.html", "DE/arzneimittel/atmp/atmp-node.html", "DE/arzneimittel/blutprodukte/blutprodukte-node.html", "DE/arzneimittel/gewebezubereitungen/gewebezubereitungen-node.html", "DE/arzneimittel/stammzellzubereitungen/stammzellzubereitungen-node.html", "DE/arzneimittel/weitere-arzneimittel/weitere-node.html", "DE/arzneimittel/tierarzneimittel/tierarzneimittel-node.html", "DE/arzneimittelsicherheit/arzneimittelsicherheit-node.html", "DE/arzneimittelsicherheit/pharmakovigilanz/pharmakovigilanz-node.html", "DE/arzneimittelsicherheit/haemovigilanz/haemovigilanz-node.html", "DE/arzneimittelsicherheit/gewebevigilanz/gewebevigilanz-node.html", "DE/arzneimittelsicherheit/ivd-vigilanz/ivd-vigilanz-node.html", "DE/arzneimittelsicherheit/atmp-vigilanz/atmp-vigilanz-node.html", "DE/arzneimittelsicherheit/veterinaermedizin/veterinaermedizin-node.html", "DE/newsroom/veroffentlichungen-arzneimittel/sicherheitsinformationen-human/sicherheitsinformationen-human-node.html", "DE/arzneimittelsicherheit/schulungsmaterial/schulungsmaterial-node.html", "DE/regulation/regulation-node.html", "DE/regulation/beratung/beratung-node.html", "DE/regulation/klinische-pruefung/klinische-pruefung-node.html", "DE/regulation/zulassung-human/zulassung-human-node.html", "DE/regulation/zulassung-veterinaer/zulassung-veterinaer-node.html", "DE/regulation/genehmigungen/genehmigungen-node.html", "DE/regulation/chargenpruefung-human/cp-hum-node.html", "DE/regulation/chargenpruefung-veterinaer/cp-vet-node.html", "DE/regulation/inspektionen/inspektionen-node.html", "DE/regulation/referenzmaterial/referenzmaterial-node.html", "DE/regulation/elektronische-einreichung/el-einreichung-node.html", "DE/regulation/gebuehren/gebuehren-node.html", "DE/regulation/prueflabor-ivd/prueflabor-ivd-node.html", "DE/regulation/melden/melden-node.html", "DE/regulation/qm/qualitaetsmanagement-node.html", "DE/forschung/forschung-node.html", "DE/forschung/forschungsgruppen/forschungsgruppen-node.html", "DE/forschung/nachwuchsfoerderung/nachwuchsfoerderung-node.html", "DE/forschung/forschungsfoerderung-drittmittel/forschungsfoerderung-node.html", "DE/forschung/forschungspreise/forschungspreise-node.html", "DE/forschung/publikationen/publikationen-node.html", "DE/forschung/gute-wissenschaftliche-praxis/gwp-node.html", "DE/newsroom/newsroom-node.html", "DE/newsroom/hp-meldungen/hp-meldungen-node.html", "DE/newsroom/pm/pressemitteilungen-node.html", "DE/newsroom/positionen/positionen-node.html", "DE/newsroom/pei-zweijahresberichte/pei-zweijahresberichte-node.html", "DE/newsroom/pflichtberichte/pflichtberichte-node.html", "DE/newsroom/social-media/social-media-node.html", "DE/newsroom/veranstaltungen/veranstaltungen-node.html", "DE/newsroom/veroffentlichungen-arzneimittel/ver-am-node.html", "DE/newsroom/videos/videos-node.html", "DE/newsroom/jahresberichte-who-cc/jb-who-cc-node.html", "DE/newsroom/dossier/coronavirus/coronavirus-node.html", "DE/newsroom/brexit/brexit-node.html", "DE/newsroom/hiv-selbsttests/hiv-selbsttests-node.html", "DE/newsroom/mitteilungen/mitteilungen-node.html", "DE/newsroom/bundesgesundheitsblatt/bgbl-node.html", "DE/service/service-node.html", "DE/service/anreise/anreise-node.html", "DE/service/bibliothek/bibliothek-node.html", "DE/service/externe-dienstleister/externe-dienstleister-node.html", "DE/service/faq/faq-node.html", "DE/service/formulare/formulare-node.html", "DE/service/geschuetzte-bereiche/geschuetzte-bereiche-node.html", "DE/service/glossar/glossar-node.html", "DE/service/karriere/karriere-node.html", "DE/service/newsletter/newsletter-node.html", "DE/service/presse/presse-node.html", "DE/service/rechtliches/rechtliches-node.html", "DE/service/spenden/spenden-node.html", "DE/arzneimittel/arzneimittel-node.html", "DE/arzneimittel/impfstoffe/impfstoffe-node.html", "DE/arzneimittel/impfstoffe/impfstoffe-node.html", "DE/arzneimittel/impfstoffe/lieferengpaesse/lieferengpaesse-node.html", "DE/arzneimittel/impfstoffe/kombinationsimpfstoffe/kombinationsimpfstoffe-node.html", "DE/arzneimittel/impfstoffe/cholera/cholera-node.html", "DE/arzneimittel/impfstoffe/denguefieber/dengue-node.html", "DE/arzneimittel/impfstoffe/diphtherie/diphtherie-node.html", "DE/arzneimittel/impfstoffe/ebola/ebola-node.html", "DE/arzneimittel/impfstoffe/fsme/fsme-node.html", "DE/arzneimittel/impfstoffe/gebaermutterhalskrebs-hpv/hpv-node.html", "DE/arzneimittel/impfstoffe/gelbfieber/gelbfieber-node.html", "DE/arzneimittel/impfstoffe/guertelrose-herpes-zoster/guertelrose--node.html", "DE/arzneimittel/impfstoffe/hib-haemophilus-influenzae-typ-b/hib-node.html", "DE/arzneimittel/impfstoffe/hepatitis-a/hepatitis-a-node.html", "DE/arzneimittel/impfstoffe/hepatitis-b/hepatitis-b-node.html", "DE/arzneimittel/impfstoffe/influenza-grippe/influenza-node.html", "DE/arzneimittel/impfstoffe/japanische-enzephalitis/japanische-enzephalitis-node.html", "DE/arzneimittel/impfstoffe/masern/masern-node.html", "DE/arzneimittel/impfstoffe/meningokokken/meningokokken-node.html", "DE/arzneimittel/impfstoffe/milzbrand/milzbrand-node.html", "DE/arzneimittel/impfstoffe/mumps/mumps-node.html", "DE/arzneimittel/impfstoffe/pertussis-keuchhusten/pertussis-node.html", "DE/arzneimittel/impfstoffe/pneumokokken/pneumokokken-node.html", "DE/arzneimittel/impfstoffe/pocken/pocken-node.html", "DE/arzneimittel/impfstoffe/poliomyelitis-kinderlaehmung/polio-node.html", "DE/arzneimittel/impfstoffe/roeteln/roeteln-node.html", "DE/arzneimittel/impfstoffe/rotavirus-infektionen/rotavirus-node.html", "DE/arzneimittel/impfstoffe/rsv/respiratorisches-synzytial-virus-node.html", "DE/arzneimittel/impfstoffe/tetanus-wundstarrkrampf/tetanus-node.html", "DE/arzneimittel/impfstoffe/tollwut/tollwut-node.html", "DE/arzneimittel/impfstoffe/typhus/typhus-node.html", "DE/arzneimittel/impfstoffe/varizellen-windpocken/windpocken-node.html", "DE/arzneimittel/allergene/allergene-node.html", "DE/arzneimittel/antikoerper/antikoerper-node.html", "DE/arzneimittel/atmp/atmp-node.html", "DE/arzneimittel/blutprodukte/blutprodukte-node.html", "DE/arzneimittel/gewebezubereitungen/gewebezubereitungen-node.html", "DE/arzneimittel/stammzellzubereitungen/stammzellzubereitungen-node.html", "DE/arzneimittel/weitere-arzneimittel/weitere-node.html", "DE/arzneimittel/tierarzneimittel/tierarzneimittel-node.html", "/SharedDocs/Downloads/DE/arzneimittel/kurzuebersicht-zentral-beschaffter-covid-19-impfstoffprodukte.pdf?__blob=publicationFile&v=19", "DE/arzneimittel/impfstoffe/covid-19/covid-19-node.html?cms_gts=221094_list%253Dtitle_text_sort%252Bdesc", "DE/arzneimittel/impfstoffe/covid-19/covid-19-node.html?cms_gts=221094_list%253Dheader_text_sort%252Basc", "DE/arzneimittel/impfstoffe/covid-19/covid-19-node.html?cms_gts=221094_list%253DteaserText_text_sort%252Basc", "DE/arzneimittel/impfstoffe/covid-19/covid-19-node.html?cms_gts=221094_list%253Dcl2RespTargets_Zusatz_sort%252Basc", "DE/arzneimittel/impfstoffe/covid-19/covid-19-node.html?cms_gts=221094_list%253DaltText_str_sort%252Basc", "DE/arzneimittel/impfstoffe/covid-19/covid-19-node.html?cms_gts=221094_list%253DdateOfIssue_dt%252Basc", "https://www.ema.europa.eu/en/medicines/human/EPAR/bimervax", "https://www.ema.europa.eu/documents/product-information/bimervax-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty", "https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_de.pdf", "https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_en.pdf", "/SharedDocs/Downloads/DE/newsroom/veroeffentlichungen-arzneimittel/rhb/21-07-19-covid-19-comirnaty-und-spikevax.pdf?__blob=publicationFile&v=5", "/SharedDocs/schulungsmaterial/Comirnaty-Schulungsmaterial-Aerzte_Version-1-201_Information.pdf?__blob=publicationFile&v=3", "https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty", "https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_de.pdf", "https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty", "https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_de.pdf", "https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty", "https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_de.pdf", "https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty", "https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_de.pdf", "https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty", "https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_de.pdf", "https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty", "https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_de.pdf", "https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty", "https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_de.pdf", "https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty", "https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_de.pdf", "https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/comirnaty", "https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_de.pdf", "https://www.ema.europa.eu/documents/product-information/comirnaty-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-inactivated-adjuvanted-valneva", "https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-product-information_de.pdf", "https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-inactivated-adjuvanted-valneva", "https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-product-information_de.pdf", "https://www.ema.europa.eu/en/documents/product-information/covid-19-vaccine-inactivated-adjuvanted-valneva-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/jcovden-previously-covid-19-vaccine-janssen", "https://www.ema.europa.eu/documents/product-information/jcovden-previously-covid-19-vaccine-janssen-epar-product-information_de.pdf", "https://www.ema.europa.eu/documents/product-information/jcovden-previously-covid-19-vaccine-janssen-epar-product-information_en.pdf", "/SharedDocs/Downloads/DE/newsroom/veroeffentlichungen-arzneimittel/rhb/21-10-13-covid-19-vaccine-janssen.pdf?__blob=publicationFile&v=2", "/SharedDocs/Downloads/DE/newsroom/veroeffentlichungen-arzneimittel/rhb/21-07-19-covid-19-vaccine-janssen.pdf?__blob=publicationFile&v=4", "/SharedDocs/Downloads/DE/newsroom/veroeffentlichungen-arzneimittel/rhb/21-04-26-covid-19-vaccine-janssen.pdf?__blob=publicationFile&v=3", "https://www.ema.europa.eu/en/medicines/human/EPAR/nuvaxovid", "https://www.ema.europa.eu/en/documents/product-information/nuvaxovid-epar-product-information_de.pdf", "https://www.ema.europa.eu/en/documents/product-information/nuvaxovid-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-moderna", "https://www.ema.europa.eu/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_de.pdf", "https://www.ema.europa.eu/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_en.pdf", "/SharedDocs/Downloads/DE/newsroom/veroeffentlichungen-arzneimittel/rhb/21-07-19-covid-19-comirnaty-und-spikevax.pdf?__blob=publicationFile&v=5", "https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-moderna", "https://www.ema.europa.eu/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_de.pdf", "https://www.ema.europa.eu/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-moderna", "https://www.ema.europa.eu/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_de.pdf", "https://www.ema.europa.eu/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-moderna", "https://www.ema.europa.eu/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_de.pdf", "https://www.ema.europa.eu/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-moderna", "https://www.ema.europa.eu/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_de.pdf", "https://www.ema.europa.eu/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-moderna", "https://www.ema.europa.eu/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_de.pdf", "https://www.ema.europa.eu/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-moderna", "https://www.ema.europa.eu/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_de.pdf", "https://www.ema.europa.eu/documents/product-information/spikevax-previously-covid-19-vaccine-moderna-epar-product-information_en.pdf", "https://www.ema.europa.eu/en/medicines/human/EPAR/covid-19-vaccine-astrazeneca", "https://www.ema.europa.eu/documents/product-information/vaxzevria-previously-covid-19-vaccine-astrazeneca-epar-product-information_en.pdf", "/SharedDocs/Downloads/DE/newsroom/veroeffentlichungen-arzneimittel/rhb/21-10-13-covid-19-vaccine-vaxzevria.pdf?__blob=publicationFile&v=2", "/SharedDocs/Downloads/DE/newsroom/veroeffentlichungen-arzneimittel/rhb/21-06-23-covid-19-vaccine-vaxzevria.pdf?__blob=publicationFile&v=2", "/SharedDocs/Downloads/DE/newsroom/veroeffentlichungen-arzneimittel/rhb/21-06-02-covid-19-vaccine-vaxzevria.pdf?__blob=publicationFile&v=3", "/SharedDocs/Downloads/DE/newsroom/veroeffentlichungen-arzneimittel/rhb/21-04-13-covid-19-vaccine-astrazeneca.pdf?__blob=publicationFile&v=4", "/SharedDocs/Downloads/DE/newsroom/veroeffentlichungen-arzneimittel/rhb/21-03-23-covid-19-vaccine-astrazeneca.pdf?__blob=publicationFile&v=2", "/SharedDocs/Downloads/DE/newsroom/mitteilungen/210319-aerzte-sicherheit-astrazeneca.pdf?__blob=publicationFile&v=6", "SharedDocs/Downloads/EN/newsroom-en/notification/210319-information-physicians-astrazeneca.html?nn=221090", "https://www.ema.europa.eu/en/medicines/human/EPAR/vidprevtyn-beta", "https://www.ema.europa.eu/en/documents/product-information/vidprevtyn-beta-epar-product-information_de.pdf", "https://www.ema.europa.eu/en/documents/product-information/vidvidprevtyn-beta-epar-product-information_en.pdf", "https://www.pei.de/DE/newsroom/dossier/coronavirus/coronavirus-inhalt.html?nn=169730&cms_pos=2", "https://www.pei.de/DE/newsroom/dossier/coronavirus/coronavirus-inhalt.html?cms_pos=5", "https://www.rki.de/DE/Content/Infekt/Impfen/ImpfungenAZ/COVID-19/Impfempfehlung-Zusfassung.html", "https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2022/06/Tabelle.html", "https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2021/35/Tabelle.html", "DE/home/home-node.html", "DE/arzneimittel/arzneimittel-node.html", "DE/arzneimittel/impfstoffe/impfstoffe-node.html", "DE/service-navi/seiteEmpfehlen/Functions/mailversand.html?cms_handOverParams=uriHash%253D9c03wUaIKUW3RIIMyd_9f4hedDvjNeE%25253D%2526uri%253Dhttps%25253A%25252F%25252Fwww.pei.de%25252FDE%25252Farzneimittel%25252Fimpfstoffe%25252Fcovid-19%25252Fcovid-19-node.html", "DE/arzneimittel/impfstoffe/covid-19/covid-19-node.html#Start", "DE/institut/aufgaben/aufgaben-node.html", "DE/institut/leitprinzipien/leitprinzipien-node.html", "DE/institut/organisation/organisation-node.html", "DE/institut/pei-international/pei-international-node.html", "DE/institut/who-kooperationszentren/who-kooperationszentren-node.html", "DE/institut/geschichte-paul-ehrlich-institut/geschichte-paul-ehrlich-institut-node.html", "DE/institut/paul-ehrlich/paul-ehrlich-im-portrait-node.html", "DE/institut/biologischer-verein/biologischer-verein-node.html", "DE/arzneimittel/impfstoffe/impfstoffe-node.html", "DE/arzneimittel/allergene/allergene-node.html", "DE/arzneimittel/antikoerper/antikoerper-node.html", "DE/arzneimittel/atmp/atmp-node.html", "DE/arzneimittel/blutprodukte/blutprodukte-node.html", "DE/arzneimittel/gewebezubereitungen/gewebezubereitungen-node.html", "DE/arzneimittel/stammzellzubereitungen/stammzellzubereitungen-node.html", "DE/arzneimittel/weitere-arzneimittel/weitere-node.html", "DE/arzneimittel/tierarzneimittel/tierarzneimittel-node.html", "DE/arzneimittelsicherheit/pharmakovigilanz/pharmakovigilanz-node.html", "DE/arzneimittelsicherheit/haemovigilanz/haemovigilanz-node.html", "DE/arzneimittelsicherheit/gewebevigilanz/gewebevigilanz-node.html", "DE/arzneimittelsicherheit/ivd-vigilanz/ivd-vigilanz-node.html", "DE/arzneimittelsicherheit/veterinaermedizin/veterinaermedizin-node.html", "DE/newsroom/veroffentlichungen-arzneimittel/sicherheitsinformationen-human/sicherheitsinformationen-human-node.html", "DE/arzneimittelsicherheit/schulungsmaterial/schulungsmaterial-node.html", "DE/regulation/beratung/beratung-node.html", "DE/regulation/klinische-pruefung/klinische-pruefung-node.html", "DE/regulation/zulassung-human/zulassung-human-node.html", "DE/regulation/zulassung-veterinaer/zulassung-veterinaer-node.html", "DE/regulation/genehmigungen/genehmigungen-node.html", "DE/regulation/chargenpruefung-human/cp-hum-node.html", "DE/regulation/chargenpruefung-veterinaer/cp-vet-node.html", "DE/regulation/inspektionen/inspektionen-node.html", "DE/regulation/referenzmaterial/referenzmaterial-node.html", "DE/regulation/elektronische-einreichung/el-einreichung-node.html", "DE/regulation/gebuehren/gebuehren-node.html", "DE/regulation/prueflabor-ivd/prueflabor-ivd-node.html", "DE/regulation/melden/melden-node.html", "DE/regulation/qm/qualitaetsmanagement-node.html", "DE/forschung/forschungsgruppen/forschungsgruppen-node.html", "DE/forschung/nachwuchsfoerderung/nachwuchsfoerderung-node.html", "DE/forschung/forschungsfoerderung-drittmittel/forschungsfoerderung-node.html", "DE/forschung/forschungspreise/forschungspreise-node.html", "DE/forschung/publikationen/publikationen-node.html", "DE/newsroom/hp-meldungen/hp-meldungen-node.html", "DE/newsroom/pm/pressemitteilungen-node.html", "DE/newsroom/positionen/positionen-node.html", "DE/newsroom/pei-zweijahresberichte/pei-zweijahresberichte-node.html", "DE/newsroom/pflichtberichte/pflichtberichte-node.html", "DE/newsroom/social-media/social-media-node.html", "DE/newsroom/veranstaltungen/veranstaltungen-node.html", "DE/newsroom/veroffentlichungen-arzneimittel/ver-am-node.html", "DE/newsroom/videos/videos-node.html", "DE/newsroom/jahresberichte-who-cc/jb-who-cc-node.html", "DE/newsroom/dossier/coronavirus/coronavirus-node.html", "DE/newsroom/brexit/brexit-node.html", "DE/newsroom/hiv-selbsttests/hiv-selbsttests-node.html", "DE/newsroom/mitteilungen/mitteilungen-node.html", "DE/service/anreise/anreise-node.html", "DE/service/bibliothek/bibliothek-node.html", "DE/service/externe-dienstleister/externe-dienstleister-node.html", "DE/service/formulare/formulare-node.html", "DE/service/geschuetzte-bereiche/geschuetzte-bereiche-node.html", "DE/service/glossar/glossar-node.html", "DE/service/karriere/karriere-node.html", "DE/service/newsletter/newsletter-node.html", "DE/service/presse/presse-node.html", "DE/service/rechtliches/rechtliches-node.html", "DE/service/spenden/spenden-node.html", "DE/service-navi/gebaerdensprache/gebaerdensprache-node.html", "DE/service-navi/leichteSprache/leichtesprache-node.html", "DE/service-navi/barrierefreiheit/barrierefreiheit-node.html", "DE/service-navi/kontakt/kontakt_node.html", "DE/service-navi/sitemap/sitemap_node.html", "DE/service-navi/impressum-pei/impressum-node.html", "DE/service-navi/datenschutz/datenschutz-node.html"]}